1% CAA was added to this media, along with NH4Cl, as nitrogen source. Spot inoculation of V. paradoxus EPS, P. aeruginosa PAO1, and Escherichia coli S17-1 on this swarming agar was performed (Fig 1). V. paradoxus EPS and P. aeruginosa PAO1 show strong swarming activity on this media, although the patterns are strikingly different. E. coli S17-1 shows no swarming, but robust growth, on this medium. Using gradient plates, we determined that glucose was not a suitable substrate

for swarming on FW based media using NH4Cl as nitrogen source (not shown). Figure 1 Variovorax paradoxus displays swarming motility. buy Trichostatin A Swarming plates with glucose and casamino acids inoculated with drops of P. aeruginosa PAO-1 (A), V. paradoxus EPS (B), or E. coli S17-1 (C). Inhibition of Swarming

with Congo Red Swarming requires the presence of flagellar activity, which is inhibited by Congo Red (CR) [40]. Supplementing plates with ≥ 50 μg/L CR had a strong inhibitory effect on the swarming phenotype (Fig 2). The colony did expand in diameter over a 48 h period under CR conditions, but at a much lower rate, consistent with simple growth based expansion. The microscopic analysis of the colony edges (Fig 3E–H) shows that the morphology of the edge differs markedly on plates containing CR. Robust growth of V. paradoxus EPS was observed under all CR Rucaparib solubility dmso treatment conditions (Fig 3A–D). Figure 2 Swarming of V. paradoxus EPS is inhibited in a dose dependent manner by the presence of Congo Red in the agar. Plates containing doses of Congo Red ranging from 1–1000 μg/L were incubated at 30°C either A) under ambient atmospheric humidity or B) in a humidified glass dish. Symbols in both panels:

No CR (black diamond), 1 μg/L CR (open square), 10 μg/L CR (filled triangle), 50 μg/L CR (×), 100 μg/L(*), 500 μg/L CR (open circle), 1000 μg/L (+). Swarm diameter measured in triplicate, reported as mean ± SEM. Figure 3 Humidity affects response to Congo Red swarming inhibition. A-D) gross morphology of V. paradoxus EPS on plates incubated at 30°C on media containing 0, 10,100, and 500 μg/L CR after 48 h. E-H) Edge images from the same culture conditions at 24 h. I-L) gross morphology of 48 h cultures on identical media incubated at 30°C in a humidified chamber. M-P) edge images from the humidified chamber incubated cultures at 24 h. Scale bar = 25 Bcl-2 inhibitor microns. Role of a wetting agent in swarming Swarming is dependent on the presence of a wetting agent, which can be seen spreading on the plate (Fig 4A, B). Wetting agent is observed spreading well in advance of the colony on media containing inhibitory levels of CR (Fig 4B). The wetting agent is evident on plates without CR during the first 2d of growth (Fig 4A), and the wetting agent reduces the surface tension of the agar plate, as shown using a qualitative water drop collapse assay (Fig 4C). Figure 4 A wetting agent is present beyond the edge of the swarm.

90 ± 0.22 μM, respectively, and infected with non-opsonized and opsonized mutant strain was 1,24 ± 0.35 and 2.20 ± 0.53 μM, respectively. Notably, NO production induced in mutant Mtb-infected MØ was attenuated by treatment with IRAK1/4 inhibitor (Figure  5B). As was the case for other parameters, DMSO (0.5%) had no effect on NO production by resting or IFN-γ-activated JQ1 MØ (0.40 ± 0.2

μM vs. 0.37 ± 0.2 μM nitrite in the presence and absence of DMSO, respectively). Figure 5 NO production by infected MØ. (A) Resting MØ and IFN-γ-activated MØ were infected with wild-type, ∆kstD, or ∆kstD-kstD strains for 2 hours without inhibitors. (B) Resting MØ were pre-incubated with IRAK1/4 inhibitor for 1 hour prior to infection with ∆kstD. After culturing for 2 days, the concentration

of nitrite, a stable metabolite of NO, was assessed in culture supernatants using the Griess reagent. The data are presented as nitrite concentration, expressed as means (μM) ± SEMs (n = 6; *p ≤ 0.03, strain vs. none [MØ in CM]; Wilcoxon’s signed-rank test). ops – bacteria opsonized, non-ops – bacteria non-opsonized; none – MØ in culture medium (control). TNF-α and IL-10 production by MØ infected with wild-type, ΔkstD, or ΔkstD-kstD strains We found no difference in the production of TNF-α between resting and IFN-γ-activated MØ infected with either wild-type or mutant strains (Figure  6A). Similarly, resting MØ produced equal amounts of IL-10 in BIBW2992 response to the infection with wild-type Mtb or ΔkstD strain. However, the ΔkstD strain, both opsonized and non-opsonized, learn more stimulated IFN-γ-activated MØ to release significantly higher amounts of IL-10 (20 ± 2 and 28 ± 6 pg/ml, respectively) than did wild-type (13 ± 2 and 15 ± 4 pg/ml, respectively) or complemented strains (12 ± 4 and 14 ± 5 pg/ml, respectively) (Figure  6B). Furthermore, resting MØ infected with wild-type Mtb produced higher amounts of IL-10 than did IFN-γ-activated MØ. In the absence of Mtb infection, resting and IFN-γ-activated MØ released relatively low amounts of TNF-α (11.0 ± 3.0 and 8.2 ± 2.2 pg/ml for resting and activated MØ, respectively) and IL-10 (1.3 ± 0.4 and 2.8 ± 0.3 pg/ml for resting and activated

MØ, respectively). Figure 6 TNF-α and IL-10 production by infected MØ. Resting MØ and IFN-γ-activated MØ were infected with wild-type, ∆kstD, or ∆kstD-kstD strains for 2 hours and then cultured for 1 day. The amount of released TNF-α (A) and IL-10 (B) was assessed in culture supernatants using ELISA kits. Data are presented as means (pg/ml) ± SEMs (n = 5; *p ≤ 0.02, ∆kstD vs. wild-type or ∆kstD-kstD; Mann–Whitney U test). ops – bacteria opsonized, non-ops – bacteria non-opsonized. Discussion It is well documented that Mtb metabolizes cholesterol, though the role of this metabolism in pathogenicity remains unclear. Various Mtb mutants defective in the ability to transport or degrade cholesterol have been previously investigated in respect to possible attenuation of the infection process.

University of California Press, Berkeley, 542 p Edwards GE, Walker DA (1984) Influence of glycerate on photosynthesis by wheat chloroplasts. Arch Biochem Biophys 231:124–135PubMedCrossRef Edwards GE, Robinson SP, Tyler NJC, Walker DA (1978a) Photosynthesis by isolated protoplasts, protoplast extracts, and chloroplasts of wheat. Plant Physiol 62:313–317PubMedCrossRef Edwards GE, Robinson SP, Tyler NJC, Walker DA (1978b) A requirement for chelation in obtaining functional chloroplasts of sunflower and wheat. Arch Biochem Biophys 190:412–433CrossRef ATM inhibitor Leegood RC, Walker DA (1993) Chloroplasts and protoplasts. In: Hall DO, Scurlock JMO, Bolhar-Nordenkampf HR, Leegood RC, Long SP (eds) Photosynthesis and production

in a changing environment: a field and laboratory manual. Chapman and Hall, New York, pp 128–131 Orr Decitabine cell line L, Govindjee (2010) Photosynthesis online. Photosynth Res 105:167–200PubMedCrossRef Raghavendra AS, Sage RF (eds) (2011) C4 Photosynthesis and related CO2 concentrating mechanisms, advances in photosynthesis and respiration, vol 32. Springer, Dordrecht Walker DA (1956) Malate synthesis in a cell-free extract from a Crassulacean plant. Nature 178:593–594CrossRef Walker DA (1960) Physiological studies on acid metabolism. Malic enzyme from Kalanchoe crenata; effects of carbon dioxide concentration. Biochem J 74:216–223PubMed Walker DA (1962) Pyruvate carboxylation and plant metabolism. Biol

Rev 37:215–256PubMedCrossRef Cytidine deaminase Walker DA (1964) Improved rates of carbon dioxide fixation by illuminated chloroplasts. Biochem J 92:22c–23cPubMed Walker DA (1981) Secondary fluorescence kinetics of spinach leaves in relation to the onset of photosynthetic carbon metabolism. Planta 153:273–278CrossRef Walker DA (1987) The use of the oxygen electrode and fluorescence probes in simple measurements of photosynthesis. Oxygraphics Limited, Sheffield, pp 1–145 Walker D (1988) In praise of fresh herbs. In: Kurti K, Kurti G (eds) But the crackling is superb: an anthology on food and drink

by fellows and foreign members of the royal society. Adam Hilger, Bristol, pp 169–170 Walker DA (1989) Automated measurement of leaf photosynthetic O2 evolution as a function of photon flux density. Phil Trans R Soc Lond B 323:313–326CrossRef Walker DA (1992a) Energy plants and man. Oxygraphics, Brighton Walker DA (1992b) Robert Hill. Photosynth Res 34:337–338CrossRef Walker DA (1993) Polarographic measurement of oxygen. In: Hall DO, Scurlock JMO, Bolhar-Nordenkampf HR, Leegood RC, Long SP (eds) Photosynthesis and production in a changing environment: a field and laboratory manual. Chapman and Hall, New York, pp 168–180CrossRef Walker DA (1997) Tell me where all past years are. Photosynth Res 51:1–26CrossRef Walker DA (2002a) The Z-scheme-downhill all the way. Trends Plant Sci 7:183–185PubMedCrossRef Walker DA (2002b) ‘And whose bright presence’—an appreciation of Robert Hill and his reaction.

48 Using a selective prostaglandin EP3 receptor antagonist selectively attenuated responses of mechanosensitive afferent nerves to urinary bladder distention and bladder

nociception either at central nervous system or at the peripheral level.49 High dose of protamine sulphate infused to rats intravesically for 2 weeks results in a loss of upper layer of urothelial cells, an increased of mast cells and PGE2 level, increase of urinary frequency,and decrease of voided volume.50 Urinary PGE2 levels were elevated in patients with UTI andsuccessful treatment for UTI lowers urinary PGE2 levels.51 In patients with OAB, urinary PGE2 level was also found to significantly increase and the PGE2 levels negatively correlated with

the maximum cystometric capacity.35 Recently, Yamaguchi et al. found that the urinary PGE2 level was significantly higher in patients with www.selleckchem.com/products/pci-32765.html brain disease, with or without OAB symptoms, than in healthy controls. However, urinary NVP-AUY922 mw NGF and substance P were not significantly associated with OAB as a result of brain disease.52 The role of urinary PGE2 on OAB needs further investigation. Adenosine triphosphate (ATP) and nitric oxide (NO) are released from the urothelium in the bladder. Munoz et al.53 reported that ATP release has a positive correlation, while NO release has a negative correlation with bladder contraction frequency in the rat. They suggested that urinary ATP/NO ratio may be a clinically relevant biomarker to characterize the extent of bladder dysfunction. Sugaya et al.54 further investigated whether the improvement of LUTS and urinary ATP level were related. Improvement of LUTS by treatment with alpha-1 receptor antagonist or

anti-muscarinic agent was related to decrease of urinary ATP/Cr ratio in patients with BPH or OAB. They suggested that measurement of urinary ATP can be used as a marker of pathologic bladder function. Tyagi and Chancellor proposed the hypothesis that local inflammation is a cause of and plays a central role in the etiology of the OAB. Tyagi et al.55 subjected urine from OAB patients through a test screen containing antibodies against 32 cytokines, chemokines, and growth factors to identify proteins with altered levels in their urine. A chronic feature of OAB makes it likely to be correlated with inflammation ifoxetine resulting from the body’s release of inflammatory cytokines as a result of irritation or injury.56 The physical signs of inflammation in OAB in the absence of UTI have been suggested by biopsy studies.57 Inflammation in the bladder typically involves lymphocytic mononuclear predominance restricted to the upper layers of the bladder wall, especially the sub-urothelium.58 Recent studies have shown that bladder inflammation induced by infiltrated immune cells can be further amplified by the resident cells of urothelium and detrusor through the release of chemoattractants called chemokines, such as MCP-1 and IL-8.

tuberculosis (Fig. 3G). However, we found that il10−/− BCG-vaccinated mice when challenged with aerosolized M. tuberculosis mediated significantly better bacterial control in the lungs when compared with challenged B6 BCG-vaccinated mice (Fig. 3G). These

data suggest that IL-10 expression reduces the efficacy of BCG vaccine-induced immunity against M. tuberculosis challenge. We then further determined the molecular mechanism by which BCG-induced IL-10 inhibits Th1-cell responses. PGE2 is known to induce IL-10 and inhibit IL-12 production in DCs 16. However, it is not known if BCG can induce PGE2 production in DCs and whether it impacts the generation of BCG-induced T-cell responses. We NVP-BGJ398 supplier report that BCG induced high levels of PGE2 in DC culture supernatants (Fig. 4A). PGE2 synthesis involves the release of endogenous arachidonic Ku0059436 acid and conversion to PGE2 via the rate-limiting enzyme cyclooxygenase 2 (COX2). Accordingly, cotreatment of BCG-exposed DCs with a COX2 inhibitor (Celecoxib) abrogated PGE2 production (Fig. 4A). Consistent with a role for PGE2 in IL-10

production, addition of COX2 inhibitor significantly reduced BCG-induced IL-10 levels (Fig. 4B) and increased IL-12 production (Fig. 4C). Furthermore, treatment with COX2 inhibitor was also able to reverse BCG-mediated inhibition of IFN-γ production in T cells cultured with BCG-exposed DCs (Fig. 4D) in DC–T-cell cocultures. These data show that BCG exposure induces PGE2 and downstream induction of IL-10; however, this pathway Idoxuridine also limits early IL-12 production and T-cell-derived IFN-γ responses. These data together show that the presence of BCG-induced IL-10 is detrimental to the generation of effective Th1-cell responses and vaccine-induced protection against M. tuberculosis challenge. Addition of exogenous

PGE2 is a potent inducer of IL-23 in DCs and drives the production of IL-17 in T cells in vitro 18, 19. Since PGE2 drives IL-10 in BCG-exposed DCs (Fig. 4B), we then examined whether PGE 2 had dual functions following mycobacterial exposure and can also drive IL-23 production in DCs. Accordingly, we treated BCG-exposed DCs with COX2 inhibitor and determined IL-23 levels in culture supernatants. Our data show that BCG-induced PGE 2 is critical for the induction of IL-23 since we detected decreased IL-23 production in response to BCG stimulation in COX2-treated samples (Fig. 4E). To further determine if PGE2-induced IL-23 production is required for the generation of BCG-induced Th17-cell responses, we cocultured naïve CD4+ OT-II TCR Tg T cells with BCG/OVA323–339-treated DCs in the presence or absence of COX2 inhibitor. We found BCG/OVA323–339-treated DCs primed T cells produced IL-17, whereas the addition of COX2 inhibitor significantly reduced the production of IL-17 in T-cell cultures (Fig. 4F). These data show for the first time that BCG-induced PGE2 production in DCs serves dual functions not only does it mediate IL-10 production and limit IFN-γ production (Fig.

Using bait plasmids with the IPS-1 CARD region (aa 6–136), we screened a human lung cDNA library to isolate IPS-1 CARD-interacting proteins. We identified one clone, Lenvatinib clinical trial ♯62 that encodes the DDX3 C-terminal region (aa 276–662), which included partial DEAD box and helicase superfamily C-terminal regions (Fig. 1A). Their interaction was confirmed in HEK293FT cells by immunoprecipitation

(IP), where DDX3 and IPS-1 were coupled (Fig. 1B). We confirmed that the C-terminal fragments of DDX3, at least 622-662 a.a, bound IPS-1 (data not shown). Taken together with the results of the yeast two-hybrid assay, the C-terminal portions of DDX3 directly bind the CARD-like region of IPS-1. RIG-I and MDA5 helicases also bind the IPS-1 CARD domain 4. In general, RNA helicases make a large molecular complex, and sometimes form homo- or hetero-oligomers.

RIG-I binds to LGP2 helicase, and forms homo-oligomers during Sendai virus infection 11. Hence, we examined whether DDX3 was associated with the RLR proteins by i.p. RIG-I and MDA5 co-precipitated with DDX3 (Fig. 2A), suggesting that DDX3 is involved in the complex of IPS-1 that interacts with RIG-I and/or MDA5. DDX3 bound the C-terminal helicase domain including the RD region of RIG-I (Fig. 2B). Thus, additional interaction may occur between DDX3 and RIG-I/MDA5. IPS-1 localizes to the membrane of mitochondria 6. Three-color imaging analysis indicated that DDX3 in part co-localized to the IPS-1-mitochodria check details complex in non-stimulated resting HeLa cells, which express undetectable amounts of RLR (Fig. 2C and data not shown). These results together with accumulating evidence infer that non-infected cells harbor the complex of DDX3 and IPS-1 with minimal G protein-coupled receptor kinase amounts of RIG-I/MDA5. Forced expression

of IPS-1 causes the activation of transcription from the IFN-β promoter. To ascertain the role of DDX3 in IFN-β production, we carried out reporter gene analysis to see the enhancing effect of DDX3 on IPS-1-mediated IFN-β promoter activation. Overexpression of DDX3 alone caused little activation of the promoter; however, the promoter activation was more augmented by minimal addition of DDX3 to IPS-1 than by overexpressed IPS-1 alone (Fig. 3A). This suggested that DDX3 enhanced IPS-1-mediated signaling despite the lack of RIG-I overexpression. To establish which region of DDX3 is important for IFN-β enhancer activity, partial DDX3 fragments were overexpressed with IPS-1, and IFN-β promoter activation was examined. The N-terminal region (aa 1–224, aa 224–487, aa 488–621) barely enhanced promoter activation (data not shown), but the C-terminal region (622–662) activated the promoter (Fig. 3B). These data indicated that the C-terminal region of DDX3 is important for the binding to IPS-1 and potentiation of the IPS-1 pathway. RIG-I and MDA5 are IFN-inducible proteins, only traces of which exist in an early phase (<2 h) in the cytoplasm where viral RNA replicate.

In GDC-0449 purchase the urinary continence system, urethral closure pressure for prohibiting the release of urine is produced by the urethral sphincter,

which is composed of both striated and smooth muscle cells. Recently, transurethral transplantation of stem cells derived from muscle satellite cells29–33 or adipose-derived mesenchymal cells34–36 have been widely investigated for the potential to regenerate urethral sphincters. These novel therapies have been performed in some hospitals, and the results have been similar to those with bulking agents alone. However, there is little evidence to indicate that the transplanted cells actually reconstruct muscle tissue necessary for the recovery of functional urethral sphincters. Our strategy to regenerate urethral sphincters that will inhibit urine leakage depends upon the use of autologous bone marrow-derived cells. These cells are capable of differentiating

both in vitro and in vivo along multiple pathways that include striated and smooth muscle37 as well as bone, cartilage, adipose, neural cells, tendon, and connective tissue.38–40 As secondary effects, bone marrow-derived cells can produce cytokines and growth factors that accelerate healing in damaged tissues and inhibit apoptosis and the development of fibrosis.41–46 Previously, we showed that bone marrow-derived cells of wild type mice, when implanted into freeze-injured urinary bladders of nude mice where most of the smooth muscle is lost, differentiate into smooth muscle cells.1 Contributing to the success of these experiments that used allogenically transplanted cells was the absence of an immune response in the nude INK 128 manufacturer mice. In the translation of these developing technologies to clinical therapy, the use of autologous cells are superior to allogenic cells because the autologous cells are not burdened with immunological rejection or ethics problems. In this review, we show that the implantation of autologous bone marrow-derived cells can regenerate however functional urethral sphincters

in a rabbit post-surgical ISD-related urinary incontinence-like model. We have considered many sources of cells from which to derive adult somatic stem cells that could regenerate urethral sphincters. Based on the literature, three sources seem to offer the greatest likelihood of success: muscle-derive satellite cells, adipose-derived mesenchymal cells, and bone marrow-derived cells. Among these, bone marrow-derived cells are the easiest to culture in terms of growth, capacity of differentiation, and production of cytokines and growth factors. These characteristics of bone marrow-derived cells have been demonstrated by many laboratory and clinical studies. However, an important consideration is the operation to harvest the bone marrow cells. This procedure is generally considered to have higher patient risks compared to harvesting muscle- and adipose-derived cells.

Future developments to enable dynamic in vivo imaging would be advantageous to allow in vivo quantification of variations in vessel diameters Sirolimus molecular weight down to the arteriolar level while under the influence of in vivo flow conditions and in vivo factors, both local and circulating. In particular, we are currently lacking

micro-CT evidence supporting the arteriolar level as a major contributor to vascular resistance (unpublished) potentially because vascular tone is missing from the ex vivo trees that we have studied. Nevertheless, the current ex vivo methods are effective in quantitatively and statistically evaluating the anatomic variation in branching patterns during development, and in response to genetic and environmental factors. Understanding the factors Belnacasan chemical structure regulating the growth and development of the fetoplacental arterial tree is necessary to understand why the tree fails to develop normally in human pregnancy pathologies. Given advances in micro-CT imaging and analysis, together with a growing resource of mouse models, we are poised for rapid progress. We anticipate that new insights into the etiology of fetoplacental arterial development will advance our understanding of vascular development and ultimately lead to improved pregnancy outcomes.

The authors gratefully acknowledge operating grant support from the Heart and Stroke Foundation of PDK4 Ontario (Grants NA5804 and T6297) and the Canadian Institute of Health Research (Grants MOP231389 and MOP93618). MYR was funded by an Ontario Graduate Scholarship and an Oregon Health and Science University Gerlinger Research Award. SLA was supported by the Anne and Max Tanenbaum

Chair in Molecular Medicine at Mount Sinai Hospital. Monique Y. Rennie: Dr. Rennie is a postdoctoral research fellow at the Heart Research Center of Oregon Health and Science University. She uses mouse models to explore fetoplacental vascular alterations in growth restricted fetuses. She has a particular interest in understanding how placental vascular defects alter hemodynamics, and uses chicken embryos to studies the effect of such hemodynamic changes on heart development. Dr. John G. Sled: Dr. Sled is a Senior Scientist at the Hospital for Sick Children and Associate Professor of Medical Biophysics at the University of Toronto. His research program at the Mouse Imaging Centre (http://www.mouseimaging.ca) focuses on the development of novel medical imaging technologies with applications for studying mouse models of disease and for clinical research. An area of particular interest is the patterning of the microcirculation and the role of patterning defects in disease. S. Lee Adamson: Dr. Adamson is a Principal Investigator in the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, and a Professor in Obstetrics and Gynaecology, and Physiology at the University of Toronto.

For these reasons, useful Epacadostat concentration classification tree models and diagnostic models have been promptly built up by this technique in several medical realms such as cancer, autoimmune disease, haematological disease and mental diseases [16–19]. In our study, we used the data of a training set to construct a classification tree model that help accurately discriminate patients with active TB from patients with other respiratory diseases and healthy people, and then we applied this model to a test set to verify its performance of classification. Patients.  According to the case definitions described elsewhere, 75 patients

with active TB (active TB group) and 103 individuals (non-TB group) including 43 patients with common respiratory diseases (CRD subgroup) and 60 healthy controls (HC subgroup) were recruited from 309th hospital of Chinese PLA. These patients were randomly divided into two sets: a training set and a test set. Our study was approved by the ethics committee of Peking Union Medical College Hospital, and informed consent was obtained from each patient and volunteer. Case definitions.  Diagnosis Selleckchem Z-VAD-FMK of active TB was based on several criteria as follows: (1) sputum smear positive of

acid-fast bacilli or culture positive of M.tb, (2) positive TST, (3) specific symptoms such as persistent cough, weight loss, and night sweats and (4) characteristic changes of chest X-ray (CXR) like lung with cavities in upper lobes. Sputum smear-positive TB (SPP-TB) and smear-negative TB (SNP-TB) patients were classified according to widely accepted criteria [20], and all patients with SNP-TB were ultimately confirmed if their symptoms and CXR turned better after 3 months of anti-TB treatment. TST was performed on active TB group in their first visit according to standard intradermal

Mantoux test with 5 IU purified protein derivative of Bacillus Calmette-Guerin (BCG) (Chengdu institute of biological product, Sichuan, China) and read after 72 h. An induration of ≥5 mm is considered a positive test [21]. Anyone who met the criteria above or had a history of contact with active TB patients was excluded from the non-TB Thiamine-diphosphate kinase group. To rule out latent patients with TB from this group, individuals that have received BCG vaccination before should be negative in IGRA (QuantiFERON®-TB Gold in Tube; Cellestis, Carnegie, Vic., Australia), which was performed according to the manufacturer’s instructions (cut-off value ≥ 0.35 IU/ml), and other individuals in the non-TB group should be negative of TST. In CRD subgroup, patients with lung cancer and sarcoidosis were diagnosed according to their biopsy evaluation, while patients with pneumonia, COPD, and bronchiectasia were diagnosed based on their clinical manifestations, radiographic features and prompt clinical response to regular therapy.